Fat Loss

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist originally developed for type 2 diabetes. It has since become one of the most clinically studied peptides for weight management, marketed as Ozempic and Wegovy.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone in a pulsatile, natural pattern. Often combined with Ipamorelin for synergistic effect.

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates growth hormone release with minimal effect on cortisol or prolactin, making it one of the cleaner GH-releasing peptides available.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind — approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Clinical trials have shown weight loss results exceeding those of Semaglutide, making it one of the most effective pharmacological weight management tools available.

SLU-PP-332 is a synthetic small-molecule compound (sometimes classified alongside research peptides) that activates oestrogen-related receptors (ERRα, ERRβ, ERRγ). It has attracted significant attention as a potential 'exercise mimetic' — producing metabolic adaptations similar to endurance training without physical exertion.

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It mimics the hormone amylin, which is co-secreted with insulin and plays a key role in satiety and gastric emptying. It is being studied in combination with Semaglutide (as CagriSema) for enhanced weight loss outcomes.

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) approved by the FDA for the reduction of excess abdominal (visceral) fat in HIV-positive patients with lipodystrophy. It is one of the few GHRH analogues with robust human clinical trial data.

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — making it the most mechanistically comprehensive weight management peptide in clinical development. Phase 2 trials have shown weight loss exceeding 24% of body weight, surpassing both Semaglutide and Tirzepatide.